CelLBxHealth plc
(“CelLBxHealth” or "the Company")
CellBxHealth Signs New Statement of Work with US-Based Pharmaceutical Company
Guildford, UK and Plymouth Meeting, U.S. - 14 October 2026 - CelLBxHealth plc (AIM: CLBX), a CTC intelligence company specialising in innovative circulating tumour cell (“CTC”) solutions for use in research, drug development and clinical oncology, announces that it has signed a new Statement of Work (“SOW”), under its existing Master Services Agreement with a US-based pharmaceutical company.
The SOW, valued at approximately US$65,000, covers the processing of approximately 100 patient samples using the Company’s proprietary Parsortix® platform to isolate and harvest CTCs for downstream molecular analysis, including mRNA analysis.
Parsortix’s unique, label-free microfluidic technology enriches and recovers intact CTCs, preserving valuable cellular material for further molecular characterisation. This capability provides pharmaceutical researchers with access to tumour-derived cells from a simple blood draw, supporting biomarker discovery, translational research and a deeper understanding of cancer biology.
The additional contract reflects continued engagement with an established pharmaceutical customer, further demonstrating the value of Parsortix as an enabling technology in oncology research and drug development. This supports CelLBxHealth’s strategy to expand biopharmaceutical partnerships and recurring commercial opportunities.
Dr. Jan Groen, Executive Chairman of CelLBxHealth, commented: “We are pleased to expand our relationship with our established US pharmaceutical partner. This additional agreement demonstrates the value of Parsortix in enabling advanced molecular analysis while reinforcing growing commercial demand, repeat business opportunities, and our strategy to drive sustainable revenue growth within the biopharmaceutical sector.”
For further information:
|
CelLBxHealth plc Jan Groen, Executive Chairman |
via Walbrook PR |
|
Cavendish (NOMAD and Broker) Geoff Nash / Isaac Hooper (Corporate Finance) Sunila de Silva (Corporate Broking) Nigel Birks (Life Science Specialist Sales) |
+44 (0)20 7220 0500 |
|
Walbrook PR (Investor and Media Relations) Paul McManus / Alice Woodings |
Tel: +44 (0)20 7933 8780 or CelLBx@walbrookpr.com Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 |
Notes for editors
About CelLBxHealth plc
CelLBxHealth plc is a CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology. Its patent-protected Parsortix® platform harvests CTCs from blood and can be integrated with existing laboratory instruments for comprehensive downstream analysis - including whole-cell imaging, proteomic profiling and full genomic workflows.
Commercial focus spans three revenue streams — Product Sales of the Parsortix platform and consumables through CRO and clinical lab partnerships, Laboratory Services including clinical trial support and assay development delivered from a GCLP-compliant UK facility, and Lab Developed Tests (LDTs), pursued through a combination of strategic partnerships and in-house development.
For more information, visit https://cellbxhealth.com/.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.